Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973534 | 0.97 | GAA (0.56) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL23827468 | 0.86 | MEN1 (0.43) | GAAMAPTALDH1A1HSD17B10HPGD | |
| SCHEMBL3113232 | 0.84 | GAA (0.66) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL23827481 | 0.83 | GAA (0.56) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL23827446 | 0.83 | ALDH1A1 (0.43) | GAAALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL5864698 | 0.80 | GAA (0.68) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL3113249 | 0.80 | GAA (0.71) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL16273597 | 0.80 | GAA (0.54) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL3108312 | 0.79 | GAA (0.63) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL3107873 | 0.79 | GAA (0.69) | GAAMAPK1MAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864312-B1 | NOVEL ANTI-CANCER THIOPHENE COMPOUNDS | UNIV LEUVEN KATH (BE) | 2021-09-22 | — | — | EP | claimed |
| US-9278958-B2 | Anti-cancer compounds | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2016-03-08 | — | — | US | claimed |
| US-20150126559-A1 | NOVEL ANTI-CANCER COMPOUNDS | UNIVERSITA DEGLI STUDI DI FERRARA (IT) | 2015-05-07 | — | — | US | claimed |
| EP-2864312-A2 | NOVEL ANTI-CANCER COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2015-04-29 | — | — | EP | claimed |
| WO-2013190137-A2 | NOVEL ANTI-CANCER COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-12-27 | — | — | WO | claimed |
| EP-2864312-B1 | NOVEL ANTI-CANCER THIOPHENE COMPOUNDS | UNIV LEUVEN KATH (BE) | 2021-09-22 | — | — | EP | disclosed |
| US-9278958-B2 | Anti-cancer compounds | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2016-03-08 | — | — | US | disclosed |
| US-20150126559-A1 | NOVEL ANTI-CANCER COMPOUNDS | UNIVERSITA DEGLI STUDI DI FERRARA (IT) | 2015-05-07 | — | — | US | disclosed |
| EP-2864312-A2 | NOVEL ANTI-CANCER COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2015-04-29 | — | — | EP | disclosed |
| WO-2013190137-A2 | NOVEL ANTI-CANCER COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-12-27 | — | — | WO | disclosed |
| US-8324227-B2 | Thieno[2,3-D]-pyrimidin-4(3H)-one compounds with antifungal properties and process thereof | FDC LIMITED (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2257555-B1 | THIENO[2,3-D]-PYRIMIDINE-4(3H)-ONE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND PROCESS THEREOF | NAT CHEMICAL LAB (IN) | 2012-07-04 | — | — | EP | disclosed |
| EP-2257555-A1 | THIENO[2,3-D]-PYRIMIDINE-4(3H)-ONE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND PROCESS THEREOF | National Chemical Laboratory (IN) | 2010-12-08 | — | — | EP | disclosed |
| US-20100273815-A1 | THIENO[2,3-D]-PYRIMIDIN-4(3H)-ONE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND PROCESS THEREOF | FDC LIMITED | 2010-10-28 | — | — | US | disclosed |
| WO-2009109983-A1 | THIENO[2,3-D]-PYRIMIDINE-4(3H)-ONE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND PROCESS THEREOF | NATIONAL CHEMICAL LABORATORY (IN) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273815-A1 | THIENO[2,3-D]-PYRIMIDIN-4(3H)-ONE COMPOUNDS WITH ANTIFUNGAL PROPERTIES AND PROCESS THEREOF | ERG28, DPM1, CYP51A1 | GAA 228/4885MAPK1 1319/4885MAPT 2865/4885 |
| US-20150126559-A1 | NOVEL ANTI-CANCER COMPOUNDS | ATP5F1A, TP53, ABCF1 | GAA 1316/4885MAPK1 1882/4885MAPT 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.